Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

22 trials with published results (29%)

Research Maturity

51 completed trials (67% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

6.6%

5 terminated out of 76 trials

Success Rate

91.1%

+4.6% vs benchmark

Late-Stage Pipeline

36%

27 trials in Phase 3/4

Results Transparency

43%

22 of 51 completed with results

Key Signals

22 with results91% success

Data Visualizations

Phase Distribution

59Total
Not Applicable (17)
Early P 1 (1)
P 1 (2)
P 2 (12)
P 3 (7)
P 4 (20)

Trial Status

Completed51
Unknown10
Recruiting7
Terminated5
Active Not Recruiting1
Withdrawn1

Trial Success Rate

91.1%

Benchmark: 86.5%

Based on 51 completed trials

Clinical Trials (76)

Showing 20 of 20 trials
NCT06577779Phase 4RecruitingPrimary

An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening

NCT06743425Not ApplicableRecruitingPrimary

A Pilot Study of a Remote ADHD Monitoring Program

NCT06185985Phase 4CompletedPrimary

Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms

NCT04781140Phase 4RecruitingPrimary

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

NCT07327775Recruiting

Fibromyalgia Disease Burden in Mothers of Children With Attention-Deficit/Hyperactivity Disorder

NCT07242625Not ApplicableRecruitingPrimary

A Pilot Study on Efficacy of Digital Therapeutic NDTx-02 for Executive Function in Children and Adolescents With ADHD or ASD

NCT06376331Phase 1RecruitingPrimary

Washed Microbiota Transplantation for Attention-deficit/Hyperactivity Disorder

NCT07044609Phase 4Not Yet RecruitingPrimary

A Study to Assess the Effectiveness and Safety of Clonidine Extended-Release OnydaTM XR in Children With ADHD and ODD

NCT02736656Phase 3Active Not RecruitingPrimary

Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

NCT01342445Phase 4CompletedPrimary

Effects of LDX on Functioning of College Students With ADHD

NCT06115603Phase 2RecruitingPrimary

The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder

NCT05778526Not ApplicableCompleted

Social Virtual-reality on Enhancing Social Interaction Skills in Children With Attention-deficit/Hyperactivity Disorder

NCT05257265Phase 3CompletedPrimary

A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder

NCT02096952Phase 4CompletedPrimary

Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD

NCT04143217Phase 3CompletedPrimary

Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD

NCT06064942Not ApplicableCompletedPrimary

Multiple Family Narrative Therapy for Chinese Families of Children With Attention Deficit Hyperactivity Disorder

NCT04507204Phase 4TerminatedPrimary

Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT04880304Not ApplicableCompleted

Effects of Subconcussive Head Impacts on Neural Integrity and Function in ADHD

NCT05568446Not ApplicableUnknownPrimary

Social VR Based Intervention on Enhancing Social Interaction Skills in Children With AD/HD

NCT05502471Not ApplicableCompletedPrimary

Occludin and Zonulin in Attention-deficit/Hyperactivity Disorder

Scroll to load more

Research Network

Activity Timeline